
PMID- 34064455
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210615
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 5
DP  - 2021 May 4
TI  - Age-Specific Seasonal Influenza Vaccine Effectiveness against Different Influenza 
      Subtypes in the Hospitalized Population in Lithuania during the 2015-2019 
      Influenza Seasons.
LID - 10.3390/vaccines9050455 [doi]
LID - 455
AB  - BACKGROUND: Continuous monitoring of seasonal influenza vaccine effectiveness 
      (SIVE) is needed due to the changing nature of influenza viruses and it supports 
      the decision on the annual update of vaccine composition. Age-specific SIVE was 
      evaluated against different influenza subtypes in the hospitalized population in 
      Lithuania during four influenza seasons. METHODS: A test-negative case-control 
      study design was used. SIVE and its 95% confidence intervals (95% CI) were 
      calculated as (1 - odds ratio (OR)) x 100%. RESULTS: Adjusted SIVE in 
      18-64-year-old individuals against influenza A, A(H1N1)pdm09 and B/Yamagata were 
      78.0% (95% CI: 1.7; 95.1%), 88.6% (95% CI: -47.4; 99.1%), and 76.8% (95% CI: 
      -109.9; 97.4%), respectively. Adjusted SIVE in individuals aged 65 years and 
      older against influenza A, influenza B, and B/Yamagata were 22.6% (95% CI: -36.5; 
      56.1%), 75.3% (95% CI: 12.2; 93.1%) and 73.1% (95% CI: 3.2; 92.5%), respectively. 
      Unadjusted SIVE against influenza A(H3N2) among 18-64-year-old patients was 44.8% 
      (95% CI: -171.0; 88.8%) and among those aged 65 years and older was 5.0% (95% CI: 
      -74.5; 48.3%). CONCLUSIONS: Point estimates suggest high SIVE against influenza A 
      in 18-64-year-old participants, and against influenza B and B/Yamagata in those 
      65 years old and older.
FAU - Kuliese, Monika
AU  - Kuliese M
AUID- ORCID: 0000-0002-4601-4585
AD  - Department of Infectious Diseases, Lithuanian University of Health Sciences, 
      Baltijos Street 120, 47116 Kaunas, Lithuania.
FAU - Mickiene, Aukse
AU  - Mickiene A
AD  - Department of Infectious Diseases, Lithuanian University of Health Sciences, 
      Baltijos Street 120, 47116 Kaunas, Lithuania.
FAU - Jancoriene, Ligita
AU  - Jancoriene L
AUID- ORCID: 0000-0001-6488-6312
AD  - Clinic of Infectious Diseases and Dermatovenerology, Faculty of Medicine, 
      Institute of Clinical Medicine, Vilnius University, Santariskiu Street 14, 08406 
      Vilnius, Lithuania.
AD  - Center of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, 
      Santariskiu Street 14, 08406 Vilnius, Lithuania.
FAU - Zablockiene, Birute
AU  - Zablockiene B
AD  - Clinic of Infectious Diseases and Dermatovenerology, Faculty of Medicine, 
      Institute of Clinical Medicine, Vilnius University, Santariskiu Street 14, 08406 
      Vilnius, Lithuania.
AD  - Center of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, 
      Santariskiu Street 14, 08406 Vilnius, Lithuania.
FAU - Gefenaite, Giedre
AU  - Gefenaite G
AD  - Department of Infectious Diseases, Lithuanian University of Health Sciences, 
      Baltijos Street 120, 47116 Kaunas, Lithuania.
AD  - Department of Health Sciences, Faculty of Medicine, Lund University, Box 157, 
      22100 Lund, Sweden.
FAU - Study Group
AU  - Study Group
LA  - eng
GR  - agreement No. SEN-03/2015/Research Council of Lithuania/
GR  - 634446/European Commission Horizon 2020 program/
GR  - Network/I-MOVE+ (Influenza Monitoring Vaccines Effectiveness in Europe in 
      Elderly)/
PT  - Journal Article
DEP - 20210504
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8147944
OTO - NOTNLM
OT  - hospital surveillance
OT  - influenza
OT  - laboratory-confirmed
OT  - older people
OT  - risk groups
OT  - severe outcomes
OT  - underlying conditions
COIS- Authors declare no conflict of interest. Ligita Jancoriene received consulting 
      fees and honorarium for lectures and payment for conducting a clinical study from 
      Merck Sharp & Dohme outside the submitted work; the registration fee of the 
      virtual meeting "HIV Glazgow 2020"; consulting fees, honorarium for lectures and 
      registration fee of "The Digital International Liver Congress 2020"-AbbVie; 
      honorarium for lectures and registration fee of virtual meeting "ID week 
      2020"-Pfizer; honorarium for lectures and registration fee of virtual meeting 
      "7th ESWI Influenza conference" (ESWL 2020)-Sanofi. Aukse Mickiene received 
      honorarium for lectures on meningococcal, pneumococcal infection, and tick-borne 
      encephalitis at the local scientific conferences and educational workshops in 
      Lithuania-Pfizer; consulting fees, honorarium for lectures on HIV treatment and 
      prevention in Lithuania-GSK; grant for the Independent Investigator-Initiated 
      Research (Project Code/PO/Tracking Number WI236259; Pfizer R&D 
      Investigator-Initiated Research program 
      (https://www.pfizer.com/science/collaboration/investigator-initiated-research, 
      accessed on 3 May 2021) for the scientific project "A prospective study on the 
      long-term outcome and pathogenesis of tick-borne encephalitis".
EDAT- 2021/06/03 06:00
MHDA- 2021/06/03 06:01
PMCR- 2021/05/04
CRDT- 2021/06/02 01:09
PHST- 2021/03/28 00:00 [received]
PHST- 2021/04/23 00:00 [revised]
PHST- 2021/04/30 00:00 [accepted]
PHST- 2021/06/02 01:09 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/03 06:01 [medline]
PHST- 2021/05/04 00:00 [pmc-release]
AID - vaccines9050455 [pii]
AID - vaccines-09-00455 [pii]
AID - 10.3390/vaccines9050455 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 May 4;9(5):455. doi: 10.3390/vaccines9050455.
